Log In or Register to Join The Conversation!
  • This topic has 1 voice and 0 replies.
Viewing 0 reply threads
  • Author
    Posts
    • #12620

      Spherix Global Insights’ 2nd annual report on MS medications and their use in the U.S. found that oral disease-modifying therapies are still in wide use among newly diagnosed patients but Ocrevus and generics are rising competitors.

      Click here to find out more about this report!

      What do you think about this news?

Viewing 0 reply threads
  • You must be logged in to reply to this topic.
Copyright © 2017-2020 All rights reserved.

©2020 KLEO Template a premium and multipurpose theme from Seventh Queen

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending
or

Log in with your credentials

or    

Forgot your details?

or

Create Account